Please use this identifier to cite or link to this item: https://biore.bio.bg.ac.rs/handle/123456789/814
Title: Design and in vitro biological evaluation of a novel organotin(IV) complex with 1-(4-carboxyphenyl)-3-ethyl-3-methylpyrrolidine-2,5-dione
Authors: Pantelić, Nebojša D.
Zmejkovski, Bojana B.
Žižak, Željko
Banjac, Nebojša R.
Božić, Bojan 
Stanojković, Tatjana P.
Kaluđerović, Goran N.
Issue Date: 1-Jan-2019
Rank: M22
Journal: Journal of Chemistry
Abstract: 
© 2019 Nebojša D. Pantelić et al. A novel triphenyltin(IV) compound with 1-(4-carboxyphenyl)-3-ethyl-3-methylpyrrolidine-2,5-dione was synthesized and characterized by IR, NMR spectroscopy, mass spectrometry, and elemental analysis. In vitro anticancer activity of ligand precursor and synthesized organotin(IV) compound was determined against tumor cell lines: Human adenocarcinoma (HeLa), human myelogenous leukemia (K562), and human breast cancer (MDA-MB-453), using microculture tetrazolium test (MTT) assay. The results indicate that complex exhibited very high antiproliferative activity against all tested cell lines with IC50 values in the range of 0.22 to 0.53 μM. The highest activity organotin(IV) compound expressed against the HeLa cells (IC50 = 0.22 ± 0.04 μM). The ligand precursor did not show anticancer activity (IC50 > 200 μM). Furthermore, fluorescence microscopy analysis of HeLa cells reveal that organotin(IV) complex induced apoptosis as a mode of cell death, which is consistent with the increase of cells in the sub-G1 phase.
URI: https://biore.bio.bg.ac.rs/handle/123456789/814
ISSN: 2090-9063
DOI: 10.1155/2019/2905840
Appears in Collections:Journal Article

Files in This Item:
File Description SizeFormat Existing users please
6 Design and In Vitro Biological Evaluation of a Novel.pdf1.85 MBAdobe PDF
    Request a copy
Show full item record

SCOPUSTM   
Citations

19
checked on Nov 16, 2024

Page view(s)

6
checked on Nov 20, 2024

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.